Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash

Original Source

Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth

Original Source

Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth

Original Source

Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes

Original Source

Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes

Original Source

Bristol-Myers Squibb Names Chief Procurement Officer

Original Source

Bristol-Myers Squibb Names Chief Procurement Officer

Original Source

Bristol-Myers Squibb Names Chief Procurement Officer

Original Source

Bristol-Myers Squibb to Announce Results for the Second Quarter of 2008 on July 24

Original Source

Bristol-Myers Squibb to Announce Results for the Second Quarter of 2008 on July 24

Original Source

Bristol-Myers Squibb Endorses PhRMA's Code on Interactions with Health Care Professionals

Original Source

Bristol-Myers Squibb Endorses PhRMA's Code on Interactions with Health Care Professionals

Original Source

Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Acquisition of Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated

Original Source

Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Kosan Biosciences Incorporated

Original Source

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5107